| 001 | 120516 | ||
| 005 | 20240228145450.0 | ||
| 024 | 7 | _ | |a 10.1080/2162402X.2017.1279777 |2 doi |
| 024 | 7 | _ | |a pmid:28405504 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC5384369 |2 pmc |
| 024 | 7 | _ | |a 2162-4011 |2 ISSN |
| 024 | 7 | _ | |a 2162-402X |2 ISSN |
| 024 | 7 | _ | |a altmetric:18831003 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-00945 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Budczies, Jan |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. |
| 260 | _ | _ | |a Austin, Tex. |c 2017 |b Landes Bioscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1533026325_1657 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Soft-tissue sarcomas (STS) are rare malignancies that account for 1% of adult cancers and comprise more than 50 entities. Current therapeutic options for advanced-stage STS are limited. Immune checkpoint inhibitors targeting the PD-1/PD-L1 signaling axis are being explored as new treatment modality in STS; however, the determinants of response to these agents are largely unknown. Using the sarcoma data set of The Cancer Genome Altas (TCGA) and an independent cohort of untreated high-grade STS, we analyzed DNA copy number status and mRNA expression of PD-L1 in a total of 335 STS cases. Copy number gains (CNG) were detected in 54 TCGA cases (21.1%), of which 21 (8.2%) harbored focal PD-L1 CNG and that were most prevalent in myxofibrosarcoma (35%) and undifferentiated pleomorphic sarcoma (34%). In the untreated high-grade STS cohort, we detected CNG in six cases (7.6%). Analysis of co-amplified genes identified a 5.6-Mb core region comprising 27 genes, including JAK2. Patients with PD-L1 CNG had higher PD-L1 expression compared with STS without CNG (fold change, 1.8; p = 0.02), an effect that was most pronounced in the setting of focal PD-L1 CNG (fold change, 3.0; p = 0.0027). STS with PD-L1 CNG showed a significantly higher mutational load compared with tumors with a diploid PD-L1 locus (median number of mutated genes; 58 vs. 40; p = 3.6E-06), and PD-L1 CNG were associated with inferior survival (HR = 1.82; p = 0.025). In contrast, T-cell infiltrates quantified by mRNA expression of CD3Z were associated with improved survival (HR = 0.88; p = 0.024) and consequently influenced the prognostic power of PD-L1 CNG, with low CD3Z levels conferring poor survival in cases with PD-L1 CNG (HR = 1.8; p = 0.049). These data demonstrate that PD-L1 GNG and elevated expression of PD-L1 occur in a substantial proportion of STS, have prognostic impact that is modulated by T-cell infiltrates, and thus warrant investigation as response predictors for immune checkpoint inhibition. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Mechtersheimer, Gunhild |b 1 |
| 700 | 1 | _ | |a Denkert, Carsten |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Klauschen, Frederick |b 3 |
| 700 | 1 | _ | |a Mughal, Sadaf S |0 0000-0003-3468-8467 |b 4 |
| 700 | 1 | _ | |a Chudasama, Priya |0 0000-0002-0754-4436 |b 5 |
| 700 | 1 | _ | |a Bockmayr, Michael |0 0000-0002-9249-4292 |b 6 |
| 700 | 1 | _ | |a Jöhrens, Korinna |b 7 |
| 700 | 1 | _ | |a Endris, Volker |b 8 |
| 700 | 1 | _ | |a Lier, Amelie |b 9 |
| 700 | 1 | _ | |a Lasitschka, Felix |b 10 |
| 700 | 1 | _ | |a Penzel, Roland |b 11 |
| 700 | 1 | _ | |a Dietel, Manfred |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Brors, Benedikt |0 P:(DE-He78)fc949170377b58098e46141d95c72661 |b 13 |u dkfz |
| 700 | 1 | _ | |a Gröschel, Stefan |0 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f |b 14 |u dkfz |
| 700 | 1 | _ | |a Glimm, Hanno |0 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9 |b 15 |u dkfz |
| 700 | 1 | _ | |a Schirmacher, Peter |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Renner, Marcus |b 17 |
| 700 | 1 | _ | |a Fröhling, Stefan |0 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d |b 18 |u dkfz |
| 700 | 1 | _ | |a Stenzinger, Albrecht |0 P:(DE-HGF)0 |b 19 |e Last author |
| 773 | _ | _ | |a 10.1080/2162402X.2017.1279777 |g Vol. 6, no. 3, p. e1279777 - |0 PERI:(DE-600)2645309-5 |n 3 |p e1279777 - |t OncoImmunology |v 6 |y 2017 |x 2162-402X |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:120516 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 0000-0002-0754-4436 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)fc949170377b58098e46141d95c72661 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)157277fe62f07df1732f9d126a51d1b9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)f0144d171d26dbedb67c9db1df35629d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ONCOIMMUNOLOGY : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ONCOIMMUNOLOGY : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)G100-20160331 |k G100 |l Translationale Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G200-20160331 |k G200 |l Angewandte Bioinformatik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G240-20160331 |k G240 |l Molekulare Leukämogenese |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)L201-20160331 |k L201 |l DKTK Berlin |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 4 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G100-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G200-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G240-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L201-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::